Chinese cancer-drug maker BeiGene in US$1.4 billion tie-up with biotech giant Celgene | South China Morning Post
![ORAL PRESENTATION: Initial results from a Phase 1 clinical study with an investigational next-generation anti- ORAL PRESENTATION: Initial results from a Phase 1 clinical study with an investigational next-generation anti-](https://www.celgene.com/content/uploads/Abstract-3-Oral-Presentation-Initial.jpg)
ORAL PRESENTATION: Initial results from a Phase 1 clinical study with an investigational next-generation anti-
![Celgene's Revlimid fails lymphoma trial, and it's more than a data shortfall: analyst | Fierce Pharma Celgene's Revlimid fails lymphoma trial, and it's more than a data shortfall: analyst | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1513954126/REVLIMID_Bottle-2.jpg/REVLIMID_Bottle-2.jpg?VersionId=sJdUL3hucuENPoJKpG0UJ1tLK4yzfixS)
Celgene's Revlimid fails lymphoma trial, and it's more than a data shortfall: analyst | Fierce Pharma
![Acceleron And Celgene Deliver Strong Results In The Phase 3 MEDALIST Trial (NASDAQ:CELG) | Seeking Alpha Acceleron And Celgene Deliver Strong Results In The Phase 3 MEDALIST Trial (NASDAQ:CELG) | Seeking Alpha](https://static.seekingalpha.com/uploads/2018/12/20/35354125-15453465360138764_origin.png)